by Fred Hutchinson Cancer CenterCredit: CC0 Public DomainA blood test intended for screening for colorectal cancer in people who are of average risk and not experiencing symptoms correctly detect
by Fred Hutchinson Cancer CenterCredit: CC0 Public DomainA blood test intended for screening for colorectal cancer in people who are of average risk and not experiencing symptoms correctly detect
byGarvan InstituteCancer cells (green) being attacked by neutrophils (red) in the collagen structure (blue) of a tumour’s microenvironment. Credit: Jacqueline Bailey / Dr Chtanova's Innate T
byGarvan InstituteCancer cells (green) being attacked by neutrophils (red) in the collagen structure (blue) of a tumour’s microenvironment. Credit: Jacqueline Bailey / Dr Chtanova's Innate T
by Violet Kieu and Kate Stern,The ConversationCredit: AI-generated imageNot all Australians with cancer are getting the fertility care they need.In 2022, it is predicted more than 8,200 Australi
by Violet Kieu and Kate Stern,The ConversationCredit: AI-generated imageNot all Australians with cancer are getting the fertility care they need.In 2022, it is predicted more than 8,200 Australi
by Kelsie Smith Hayduk,University of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainResearchers at the Del Monte Institute for Neuroscience at the University of Rochester find that mic
by Kelsie Smith Hayduk,University of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainResearchers at the Del Monte Institute for Neuroscience at the University of Rochester find that mic
by Cheryl Critchley,Monash UniversityCredit: Pixabay/CC0 Public DomainA Monash University-led trial of a new drug known as Q-122 therapy significantly reduced the number and severity of hot flas
by Cheryl Critchley,Monash UniversityCredit: Pixabay/CC0 Public DomainA Monash University-led trial of a new drug known as Q-122 therapy significantly reduced the number and severity of hot flas
byWolters Kluwer HealthTwelve-month landmark analysis of overall survival (OS) by prostate-specific antigen (PSA) decline subgroup for enzalutamide-treated men. Data cutoff: October 15, 2019. Cr
byWolters Kluwer HealthTwelve-month landmark analysis of overall survival (OS) by prostate-specific antigen (PSA) decline subgroup for enzalutamide-treated men. Data cutoff: October 15, 2019. Cr
by South Australian Health and Medical Research Institute (SAHMRI)Credit: Dan Gold on UnsplashNew research has found food could play a major role in stopping the growth of some cancers.It was previous
by South Australian Health and Medical Research Institute (SAHMRI)Credit: Dan Gold on UnsplashNew research has found food could play a major role in stopping the growth of some cancers.It was previous
byUniversity of AucklandCredit: CC0 Public DomainOld medicines, combined in new ways, are showing promise for treating bowel cancer, a group of University of Auckland researchers has found."
byUniversity of AucklandCredit: CC0 Public DomainOld medicines, combined in new ways, are showing promise for treating bowel cancer, a group of University of Auckland researchers has found."
JANUARY 12, 2024byUniversity of Texas at El PasoRenato Aguilera, Ph.D., a professor in the Department of Biological Sciences at The University of Texas at El Paso, is the principal investigator
JANUARY 12, 2024byUniversity of Texas at El PasoRenato Aguilera, Ph.D., a professor in the Department of Biological Sciences at The University of Texas at El Paso, is the principal investigator
by Tim Stephens,University of California - Santa CruzThe breast cancer drug palbociclib (grey) interacts with its target protein CDK4 (green) in this structural model. Binding of the activator p
by Tim Stephens,University of California - Santa CruzThe breast cancer drug palbociclib (grey) interacts with its target protein CDK4 (green) in this structural model. Binding of the activator p
by Kindai UniversityA study by researchers from Japan has revealed that the simultaneous administration of two antibodies with different isotypes targeting a specific membrane protein produced a syner
by Kindai UniversityA study by researchers from Japan has revealed that the simultaneous administration of two antibodies with different isotypes targeting a specific membrane protein produced a syner